Product Information
TEKTURNA 300 MG TABLET is a brand product labeled by LXO US Inc., priced at $15.0945 per EA under NDC 70839030030. Its NADAC has been published 491 times since May 10, 2017.
FDA first approved this application on Mar 5, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
LXO US Inc.NDC
70839030030
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
1/6/2026
Active Ingredients
ALISKIREN HEMIFUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA021985FDA Approved
3/5/2007
TE Code
AB
On Market Since
3/5/2007
Pharmacological Classes
Price Statistics
The NADAC for TEKTURNA 300 MG TABLET has been published 491 times since May 10, 2017, and over the history we have for it it has risen 126.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.0945 per EA |
|---|---|
| All-time high | $15.0945 (Sep 30, 2026) |
| All-time low | $6.6303 (Jun 21, 2017) |
| 52-week high | $15.0945 |
| 52-week low | $13.8480 |
| Median price | $10.7609 |
| Average price | $10.5374 |
| Largest weekly change | +15.5% (Nov 14, 2018) |
| Weeks tracked | 491 |
| Tracking since | May 10, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 61% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
LXO US Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
aliskiren hemifumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Renin Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TEKTURNA 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TEKTURNA 300 MG TABLET, manufactured by LXO US Inc., is $15.0945 per EA (NDC 70839030030), effective Sep 30, 2026.
How has the price of TEKTURNA 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for TEKTURNA 300 MG TABLET has risen 126.3%. It has been tracked across 491 weekly CMS publications since May 10, 2017.
What are the highest and lowest recorded NADAC prices for TEKTURNA 300 MG TABLET?
Since May 10, 2017, the NADAC for TEKTURNA 300 MG TABLET has ranged from a low of $6.6303 (Jun 21, 2017) to a high of $15.0945 (Sep 30, 2026), with a median of $10.7609 per EA.
Are there cheaper alternatives to TEKTURNA 300 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ALISKIREN 300 MG TABLET, is $5.8584 per EA — about 61% below TEKTURNA 300 MG TABLET.
Who manufactures TEKTURNA 300 MG TABLET?
TEKTURNA 300 MG TABLET (NDC 70839030030) is labeled by LXO US Inc., and CMS classifies it as a brand product.